Meningioma: A Review of Clinicopathological and Molecular Aspects

Kristin Huntoon, Angus Martin Shaw Toland, Sonika Dahiya

Research output: Contribution to journalReview articlepeer-review

10 Scopus citations

Abstract

Meningiomas are the most the common primary brain tumors in adults, representing approximately a third of all intracranial neoplasms. They classically are found to be more common in females, with the exception of higher grades that have a predilection for males, and patients of older age. Meningiomas can also be seen as a spectrum of inherited syndromes such as neurofibromatosis 2 as well as ionizing radiation. In general, the 5-year survival for a WHO grade I meningioma exceeds 80%; however, survival is greatly reduced in anaplastic meningiomas. The standard of care for meningiomas in a surgically-accessible location is gross total resection. Radiation therapy is generally saved for atypical, anaplastic, recurrent, and surgically inaccessible benign meningiomas with a total dose of ~60 Gy. However, the method of radiation, regimen and timing is still evolving and is an area of active research with ongoing clinical trials. While there are currently no good adjuvant chemotherapeutic agents available, recent advances in the genomic and epigenomic landscape of meningiomas are being explored for potential targeted therapy.

Original languageEnglish
Article number579599
JournalFrontiers in Oncology
Volume10
DOIs
StatePublished - Oct 23 2020

Keywords

  • clinical trials
  • immunotherapy
  • meningioma
  • molecular diagnosis
  • neurosurgery
  • pathology
  • radiation therapy
  • targeted treatment

Fingerprint

Dive into the research topics of 'Meningioma: A Review of Clinicopathological and Molecular Aspects'. Together they form a unique fingerprint.

Cite this